B. Braun Medical Inc.
|Underlying Misconduct:||Federal Food, Drug, and Cosmetic Act|
|Matter Type:||DOJ Criminal|
|Relevant Jurisdiction(s):||Eastern District of North Carolina|
|Penalties:||Fine, Restitution, Settlement Payment|
|Reporting Agencies:||USAO Eastern District of North Carolina|
|Resolution Form:||Non-Prosecution Agreement|
|Agreement Date:||May 16, 2016|
|Monitor Reference Term:||Independent Auditor/Reviewer|
|Monitorship Term:||30 Months|
|Monitor Selection Process:||
None noted in NPA; however, as it is DOJ, would presume DOJ Policy. For these reasons, some of the following entry areas could not be completed.
|Time to Propose Monitors:||N/A|
|Time to Engage Monitor:||N/A|
|Time to First Report:||90 days|
|Monitor Required Qualifications:||
|Summary of Monitor's Scope:||
Audit and assess Host Organization's compliance with the commitments to implement and maintain policies and procedures per Agreement.
|Summary of Monitor's Activities:||
Evaluate the effectiveness of internal controls, record-keeping, and policies and procedures as they relate to Host Organization's Type II PFG Quality Compliance Program, and take such reasonable steps as, in the Monitor's view, may be necessary to fulfill the Agreement mandate. Audit will include inspection of relevant docs, on-site observations (including internal controls, record-keeping, and quality procedures), meetings and interviews.
None specified; however, DOJ Policy generally requires that the Monitor not do any business with the Host Organization for a period of at least one year after the expiration of the Monitorship.